serlopitant
Menlo Therapeutics’ cough drug fails to meet primary endpoint in phase II trial
October 9, 2018Manufacturing and Production Phase II, cough, menlo therapeutics, serlopitant
The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
